PEOPLE - Organogenesis (US) makes promotion:
This article was originally published in Clinica
Tissue engineering company Organogenesis (Canton, Massachusetts) has promoted Steven Bernitz to the position of president and CEO. Mr Bernitz, who joined the company in 1999, replaces Michael Sabolinski, who will continue to serve as executive vice-president of medical and regulatory affairs and will replace Nancy Parenteau as chief scientific officer.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.